Exposure of human pulmonary microvascular endothelial cells (HPMECs) to phorbol 12-myristate 13-acetate (PMA) leads to the increase of prostaglandin H synthase (PGHS)-2 protein levels. Under same conditions and according to its constitutive nature, no significant variation of PGHS-1 protein was noted. The elevation of the intracellular cAMP rate is known to enhance PGHS-2 levels through a protein kinase A pathway in various cells. To determine whether the extracellular cAMP also regulates the inducible expression of PGHS, cultured HPMECs were exposed to cAMP alone or in combination with PMA. The PMA-induced PGHS-2 protein was attenuated by the extracellular cAMP. In addition, PGHS-2 activity evaluated through 6-keto-PGF1␣ generation, which was enhanced by PMA was inhibited by extracellular cAMP. Furthermore, in HPMEC medium, PMA-induced PGHS-2 expression was accompanied by the generation of a transferable activity (TA) able to abolish platelet aggregation. This resulting TA was dependent from PGHS-2 pathway, because NS-398, a selective inhibitor of PGHS-2, suppressed its production. The inhibitory TA released by treated HPMECs was also prevented by extracellular cAMP. The specific protein kinase A (PKA) inhibitor blocked the extracellular cAMP effect on both PMA-induced 6-keto-PGF1␣ synthesis and inhibitory TA generation, suggesting the involvement of PKA signaling at the outer surface of HPMECs. Accordingly, we established, in phosphorylation experiments, the presence of an endothelial ectoprotein kinase activity, able to phosphorylate the synthetic substrate kemptide in a cAMP-dependent mode. Reverse transcription-polymerase chain reaction analysis showed that PMA-induced PGHS-2 mRNA was markedly reduced by extracellular cAMP. Together, these findings provide the first experimental evidence that extracellular cAMP is able to reduce HPMEC PGHS-2 expression in terms of mRNA, protein, and enzyme activity through an ecto-PKA pathway. In addition, they outline the potential role of endothelial PGHS-2 in the limitation of platelet activation during inflammatory processes.
Prostaglandin H synthase (PGHS) 1 (E.C. 1.14.99.1) catalyzes the bis-oxygenation of arachidonic acid to prostaglandin H2, the committed step in prostaglandin formation (1) . The chemically unstable prostaglandin H2 is quickly converted into various prostanoids by specific enzymes. The abundance and the nature of generated prostanoids depend on tissue and cell types (e.g. prostacyclin and thromboxane A2 are the principal products generated from prostaglandin H2 in endothelial cells and platelets, respectively) (2, 3) . PGHS exists as two protein isoforms, PGHS-1 (or Cox-1) and PGHS-2 (or Cox-2), which are produced by two distinct genes. The gene for PGHS-1 is localized on chromosome 9, whereas that for PGHS-2 is on chromosome 1 (4). PGHS-1, constitutively expressed, produces prostaglandins and thromboxane A2 during physiologic activities such as homeostasis and gastroprotection. PGHS-2 is an inducible enzyme considered to be involved in the overproduction of prostanoids during inflammatory disorders (5, 6) .
The surface of cells is directly involved in cell-cell interaction and adhesion. The expression of enzymatic activities at the membrane surface may be an important way for cells to communicate and interact with their environment.
Protein phosphorylation is critical to the regulation of cellular functions (7) (8) (9) . Tetradis et al. (10) have shown that parathyroid hormone induction of PGHS-2 in MC3T3-E1 cells is mediated by the cAMP/PKA signaling pathway, which increases PGHS-2 at transcription level.
It is well known that intracellular PKA is important in the regulation of function of various cells (11) (12) (13) , but little is known on ecto-PKA activity present at the plasma membrane. In a previous study, we have demonstrated (14) the presence of an ecto-PKA activity at the surface of intact human platelets, and we have revealed its principal endogenous target as being CD36, a membrane glycoprotein interacting with adhesion molecules such as collagen and thrombospondin. The ratelimiting step for this ecto-phosphorylation activity depends on ATP and especially on cAMP. These nucleotides are intracellular constituents that may be released from platelets under well described conditions (15) and may directly act on the surrounding endothelial cells.
PGHS-2, which is involved in prostanoid synthesis in the course of inflammatory reactions, is regulated at the transcription level. It may be expressed by many nucleate cells upon challenge with PMA, LPS or inflammatory cytokines (16) .
Finally, the increase of intracellular cAMP rate enhances PGHS-2 expression in various cell types (17) (18) (19) (20) .
The objective of this study was to determine whether PMAinduced PGHS-2 expression in human pulmonary microvascular endothelial cells (HPMECs) is regulated by extracellular cAMP, through an ecto-PKA signaling pathway.
We clearly demonstrate here that extracellular cAMP is able to reduce PGHS-2 expression in adherent HPMECs at the levels of mRNA, protein, and enzyme activity through an ecto-PKA signaling pathway. In addition, our findings outline the role of inducible endothelial PGHS-2 in the potential limitation of platelet activation during inflammatory processes.
EXPERIMENTAL PROCEDURES
Materials-Reagents and materials were from the following sources: prostacyclin, cAMP, the stable prostaglandin (PG) H2 analogue U46619, PGE2, forskolin, arachidonic acid, ATP, phorbol 12-myristate 13-acetate (PMA), kemptide (Leu-Arg-Arg-Ala-Ser-Leu-Gly), natural protein kinase inhibitor peptide PKI (Thr-Thr-Tyr-Ala-Asp-Phe-IleAla-Ser-Gly-Arg-Thr-Gly-Arg-Arg-Asn-Ala-Ile-His-Asp), and anti-␤ actin antibody were purchased from Sigma. 6-keto-PGF1␣ kit, cAMP kit, anti-PGHS-1, and anti-PGHS-2 antibodies were from SPI-BIO (Massy, France). GF 109203X, a selective inhibitor of protein kinase C, was a kind gift from Dr. J. Kirilovsky (Glaxo, France). Nitrocellulose membranes (BA83) were from Schleicher & Schuell. [␥-
32 P]ATP and peroxidase-linked sheep anti-mouse IgG, ECL Western blotting detection system, biotinylated streptavidin-horseradish peroxidase complex, and biotinylated anti-mouse IgG antibody were purchased from Amersham Pharmacia Biotech. Reverse transcriptase and Taq polymerase were from Promega (Charbonnière, France) and Eurobio (Les Ulis, France), respectively. Oligodeoxynucleotides were from Genset (Paris, France). Monoclonal mouse IgG1 antibody and fluorescein isothiocyanate-goat polyclonal anti-mouse were from Dako (Glostrup, Denmark). The selective PGHS-2 inhibitor NS-398 was from Biomol (USA). Endothelial cell growth medium-microvascular medium, and microbeads coated with streptavidin and biotinylated specific endothelial lectin (Ulex Europaeus UEA I) were from TEBU (Le Perry-en Yvelines, France).
Preparation of HPMEC Culture-Healthy distal human pulmonary fragments were from the Service de Chirurgie Cardiothoracique (Prof. J. P. Couetil, Hôpital Broussais, Paris, France) and taken after obtaining voluntary consent from patients. The lingula lung fragments were immersed in sterile minimum Eagle's medium. Cell isolation and culture techniques were derived from the method of Chen et al. (21) . Briefly, the tissue was carefully dissected and was minced thoroughly in a potter. Then, preparation was centrifuged at 4°C and 500 ϫ g for 10 min, and the pellet was resuspended in endothelial cell growth mediummicrovascular medium, a selective medium for microvascular endothelial cells. HPMECs were cultured on dishes coated with 0.5% gelatin. The microvascular endothelial cells were identified according to morphological criteria (characteristic cobblestone morphology). They were purified from the primary culture by an immunomagnetic selection using the VarioMacs system (Myltenii) and microbeads coated with streptavidin and a biotinylated specific endothelial lectin, Ulex Europaeus UEA I. The cells were grown on gelatinized dishes in endothelial cell growth medium-microvascular medium. The endothelial nature of the cells was confirmed by detection of adhesive molecules, such as von Willebrand factor and VCAM-1 or ICAM-1.
Preparation of Human Platelets-Blood obtained from healthy human volunteers who had not received any medication for at least 10 days was anticoagulated with one-sixth of its final volume by a mixture of citric acid, citrate, and dextrose (7, 93 , and 139 mM, respectively, pH 6.4) containing heparin (20 IU/ml). Washed platelets were prepared according to Mustard et al. (22) , in which apyrase was omitted, and prostacyclin (10 nM) was added for the first two steps of washing procedure. Platelets were resuspended in Tyrode's buffer, and their number was adjusted to 5 ϫ 10 8 cells/ml. Measurement of PGHS Activity-Briefly, after different treatments, adherent HPMECs were washed and exposed to arachidonic acid (30 M) for 10 min. Thereafter, aliquots of incubation media were stored at Ϫ20°C for further 6-keto-PGF1␣ measurements. Amounts of 6-keto-PGF1␣, a stable nonenzymatic hydrolysis product of prostacyclin, were monitored by a specific kit according to method of Pradelles et al. (23) .
PGHS-2 activity was also evaluated by a bioactive functional method based on the ability of HPMEC transferable activity to inhibit platelet aggregation. Thus, media from arachidonic acid-activated endothelial cells were added to platelet suspensions (5.10 8 platelets/ml) pretreated with aspirin (50 M). Platelet aggregation was then triggered by the stable prostaglandin H2 analogue, U46619 (0.3 M), and aggregating responses were followed for 8 min after the addition of the stimulating agent.
Measurement of Intracellular cAMP Formation-Suspensions of HPMECs (400 l, 10 7 /ml) were exposed to PMA in the presence and in the absence of forskolin (50 M) or PGE2 (50 M) for 10 min, and then, 800 l of ethanol were added. cAMP contained in each sample was determined by specific kit according to enzyme immunoassay method of Pradelles et al. (24) .
Immunocytochemistry Analysis-The adherent HPMECs were fixed with 3.7% formol and permeabilized with 80% acetone for 5 min. Then, they were washed in phosphate-buffered saline and incubated in a humid chamber for 1 h with a specific PGHS-2 antibody (10 g/ml) or its corresponding isotype (10 g/ml). After washing, samples were incubated with fluorescein isothiocyanate-anti-mouse IgG antibody (20 g/ ml) for 1 h in a humid chamber at room temperature. The sections were examined using a Nikon Optiphot-2 microscope equipped with fluorescence and Nomarski optics, and photographs were taken with Ilford HP5, 400 ASA film using identical exposure times.
Reverse Transcription Polymerase Chain Reaction (RT-PCR) and PCR Product Analysis-Total cellular mRNA was prepared according to Chomczynski and Sacchi (25) . RT-PCR techniques were used to generate human HPMEC PGHS-2 and ␤-actin PCR products of 305 and 263 base pairs, respectively. RT was performed with hexamers and superscript RT as described by the manufacturer. PCR amplifications for PGHS-2 were done using 35 cycles (94°C for 45 s, 63°C for 40 s, and 72°C for 45 s) in 100 l of buffer containing 1.5 mM MgCl 2 , 200 M dNTPs, 20 mM Tris-HCl, pH 8.4, 50 mM KCl, and 2 units of of Taq polymerase with the following primers: 5Ј-TTCAAATGA GATTGTGG-GAAAATTGCT-3Ј and 5Ј-AGATCATCTCTGCCTGAGTATCTTT-3Ј. PCR products were subjected to agarose gel (1.5%) electrophoresis and transferred onto nylon membranes. Blots were hybridized in 5ϫ SSC (1ϫ SSC ϭ 0.15 M NaCl and 0.015 M sodium citrate), 20 mM phosphate buffer, pH 7.2, 7% SDS, and 10ϫ Denhart's reagent overnight at 49°C, with a specific PGHS-2 ␥-32 P-labeled oligodeoxynucleotide (5Ј-AGACA-GATCATAAGCGAGG-3Ј) that was previously prepared using T4 polynucleotide kinase reaction. The membranes were washed first with 0.1% SDS and 2ϫ SSC at 49°C for 20 min and then with 1ϫ SSC and 0.1% SDS at 49°C for 20 min. Finally, filters were exposed to a PhosphorImager and quantified by ImageQuant (Molecular Dynamics, Sunnywale, CA).
Analysis of Kemptide Phosphorylation-Protein kinase activity on kemptide was assayed in culture dishes containing HPMECs (10 7 cells) supplemented with [␥-32 P]ATP (10 Ci/sample), unlabeled ATP (5 M), cAMP (5 M), and paranitrophenyl phosphate (10 mM). Reactions were initiated by addition of kemptide (5 M) and were continued for 10 -15 min. In order to stop the reaction, 20 l of each sample were placed in plastic tubes containing 10 l of glacial acetic acid. Aliquots of 20 l of the reaction mixture were deposited on Whatman P-81 phosphocellulose filter papers according to Glass et al. (26) . After 30 s, the filter papers were introduced in 30% acetic acid containing 2 mM ATP for at least 60 min. The filter papers were washed three times for 15 min in acetic acid 15% and then introduced in ether/ethanol (v/v) and, finally, in ether and dried. Phosphorylation was evaluated by the determination of the radioactivity in each aliquot (filter paper) using a ␤-counter.
Immunoblotting Analysis-Immunoblot analysis was performed according to Laemmli (27) . Briefly, after gel separation, cell proteins were transferred onto nitrocellulose membranes by semidry transfer (25 mM Tris, 192 mM glycine, and 20% methanol). Membranes were blocked overnight with 5% nonfat dry milk in the following buffer (Tris 20 mM, pH 7.6, NaCl 140 mM, and 0.1% Tween 20). Blots were probed for 1 h with monoclonal antibodies anti-PGHS-1, anti-PGHS-2, or anti-␤-actin (diluted to 1/1000). The primary antibodies were removed and immunoreactive bands were visualized using a peroxidase mouse immunoglobulin antibody (diluted to 1/10.000) followed by ECL reagent.
Statistical Analysis-Statistical significance between treated and control samples was determined using Student's t test for unpaired data. Results are expressed as mean Ϯ S.E. of three to five separate experiments.
RESULTS

Enhancement of PGHS-2 Expression in HPMECs by PMA
and Its Up-regulation by Intracellular cAMP-As expected, PMA strongly increased PGHS-2 expression in HPMECs with an optimum at 10 nM. In contrast, no significant variation was observed under the same conditions for the PGHS-1 isoform (Fig. 1A) . This induction of PGHS-2 expression was abrogated by GF 109203X, a specific protein kinase C (PKC) inhibitor (28) , whereas the PGHS-1 protein level remained unmodified. A time course study showed that the induction of PGHS-2 protein, unlike ␤-actin, increased during the cell incubation with PMA (10 nM) and reached a maximum at 24 h (Fig. 1B) .
As shown in Fig. 1C , the elevation of intracellular cAMP levels evoked by PGE2 (50 M) or forskolin (50 M) increased PMA-induced PGHS-2 protein in HPMECs, under conditions where ␤-actin expression was not modified. In fact, the estimated relative amounts of PGHS-2 protein obtained from the quantitation of Western blot signals (PGHS-2/␤-actin) were 1085 Ϯ 46, 1307 Ϯ 76, and 1255 Ϯ 102 for PMA (10 nM) alone or in combination with forskolin (50 M) or PGE2 (50 M), respectively. A statistical significant increase (p Ͻ 0.05, n ϭ 3) was noted when forskolin was used. Under the same conditions, the cAMP amounts generated 10 min after the PMA addition were 271 Ϯ 27 pmol/10 7 cells for forskolin plus PMA, 138 Ϯ 48 pmol/10 7 cells for PGE2 plus PMA, and 69 Ϯ 11 pmol/10 7 cells for control PMA-treated cells (n ϭ 3). Inhibition by Extracellular cAMP of PMA-induced PGHS-2 Expression-To investigate the possible modulating role of extracellular cAMP on the induction of PGHS-2 expression, cultured HPMECs were incubated with PMA (10 nM) alone or in combination with cAMP (5 M) and ATP (5 M). As shown, immunoblotting analysis ( Fig. 2A) revealed that extracellular cAMP, which had no effect by itself, significantly inhibited PGHS-2 expression induced by PMA. Indeed, estimated relative values of PGHS-2 protein obtained from the quantitation of Western blot signals (PGHS-2/␤-actin) were 529 Ϯ 20 versus 823 Ϯ 8 for control PMA-treated cells (p Ͻ 0.01, n ϭ 3).
In related experiments, using immunofluorescence technique and an anti-PGHS-2 monoclonal antibody, we observed that PMA (10 nM) caused fluorescence staining of the adherent HPMECs. No significant staining was observed for quiescent cells (control). In accordance with immunoblotting results, cAMP added in combination with ATP, a substrate of phosphorylation, had no significant effect on the basal staining but greatly decreased the staining intensity caused by PMA (Fig.  2B) .
Effect of Extracellular cAMP on PGHS Activity-PGHS activity was evaluated through the generation of 6-keto-PGF1␣, a stable nonenzymatic hydrolysis product of prostacyclin. As established for other endothelial cell types, PMA enhances PGHS-2 activity. In the PMA-treated cells, the 6-keto-PGF1␣ generated following arachidonic acid addition was increased by about 7-fold as compared with that of untreated control cells. However, the addition of increasing concentrations of cAMP into the extracellular medium decreased progressively and significantly the 6-keto-PGF1␣ production (Fig. 3A) . PKI, a specific PKA inhibitor (29) prevented in the concentration-dependent manner this effect with an apparent calculated K i of 12 nM (Fig. 3B) .
In another set of experiments using a functional assay, we evaluated PGHS activity through the ability of generated prostanoids, particularly prostacyclin, to inhibit platelet aggregation. As shown in Fig. 4 , exposure of aspirinized platelets to media (50 l) from PMA-treated HPMECs incubated with arachidonic acid (30 M) inhibited aggregation triggered by thromboxane A2 mimetic, U46619 (0.3 M). When HPMECs were treated with PMA in association with cAMP plus ATP, the inhibition of platelet aggregation by the culture medium did not occur. This effect due to the extracellular cAMP plus ATP on the PMA-induced HPMEC response was also prevented by PKI. Finally, NS-398 (30 M), a specific potent inhibitor of PGHS-2 (30), abolished the generation of the inhibitory transferable activity induced by PMA.
Increase of PGHS-2 mRNA in PMA-treated HPMECs and Its Modulation by Extracellular cAMP-
To assess whether extracellular cAMP also modulates PGHS-2 mRNA, we performed RT-PCR on total RNA prepared from HPMECs treated for 3-24 h under various conditions.
Blots of PCR products hybridized with a PGHS-2-specific ␥-32 P-labeled oligodeoxynucleotide probe revealed products of 305 base pairs in HPMECs. As expected, treatment of the cells by PMA, increased PGHS-2 mRNA levels under conditions where only small amounts were detected in untreated control cells. PMA-induced PGHS-2 mRNA, which is increased in a time-dependent manner, reached a maximum at 6 h and then back to its basal level at 24 h (data not shown). The effect of PMA on the mRNA PGHS-2 expression was attenuated by extracellular cAMP. The spot quantification by ImageQuant of radioactive intensity, corresponding to relative PGHS-2 compared with ␤-actin, clearly established this effect (Fig. 5) .
Detection of PKA Activity at the Outer Surface of HPMECs-To investigate the existence of endothelial ecto-PKA activity by which cAMP may decrease PMA-induced PGHS-2 expression, kemptide, a specific PKA substrate (31) , was added to the extracellular medium. Thus, the incubation of kemptide (5 M) with intact HPMECs in the presence of [␥-
32 P]ATP (10 Ci), ATP (5 M) and cAMP (5 M) resulted in an important incorporation of the radioactivity into this exogenous substrate. However, no significant increase of the kemptide phosphorylation occurred when exogenous cAMP was omitted or when specific PKA inhibitor peptide PKI was added to the extracellular medium (Fig. 6 ).
DISCUSSION
Levels of PGHS-2 RNA messenger and polypeptide are undetectable in most tissues under physiological conditions, but they can be induced rapidly in a wide variety of cells in response to inflammatory stimuli (32) (33) (34) . In contrast, PGHS-1, which is expressed at relatively high levels in quiescent cells, remains essentially constant, even after exposure to mitogens (35, 36) .
In the present study, the expression of PGHS-2 was investigated at the mRNA, protein and enzyme activity levels. In accordance with the work of Vezza et al. (37) , increase of PGHS-2 expression was observed in response to the tumor promotor PMA in a concentration-and a time-dependent manner. However, PGHS-1 expression remained unchanged or increased only slightly in response to PMA. As expected, PMAinduced PGHS-2 expression in HPMECs was strictly dependent on PKC pathway, because GF 109203X, a selective PKC inhibitor (26) , abrogated this response. It is important to outline that PMA-induced PGHS-2 mRNA, which peacked at 6 h, decreased during incubation. This effect can be attributed to mRNA instability because the 3Ј untranslated region of PGHS-2 mRNA possesses repetitive AUUUA motifs, known for their ability to enhance mRNA degradation (38, 39) .
Different studies reported that the increase of intracellular cAMP level enhanced PGHS-2 expression in various cell types (17) (18) (19) (20) . In agreement with these findings, we established that forskolin, which enhances intracellular cAMP level by stimulating adenylyl cyclase, significantly increases PGHS-2 expres- sion in HPMECs. In contrast to findings reported for other cell types (17) (18) (19) (20) , the limited PGHS-2 protein increase, triggered by PGE2 or forskolin exposition, could be correlated to the lower amount of cAMP formed in HPMECs in response to either of these adenylyl cyclase activators. Indeed, in a comparative study, we have measured cAMP levels in both HPMECs and human blood platelets under adenylyl cyclase activation and/or cAMP-specific phosphodiesterase inhibition. In all cases, HPMECs generated only small amounts of cAMP compared with those produced by human blood platelets (data not shown). In contrast, using a murine macrophage cell line, Pang and Hoult (40) reported that adenylyl cyclase activators, such as PGE2, PGI2, and forskolin, suppressed the induction of PGHS-2 expression by endotoxin, suggesting that the cAMP effect was dependent from cell type. The effect of intracellular cAMP may be mediated by the cAMP response element, described at the promoter of human PGHS-2 gene (41, 42) .
The main objective of this study was to determine whether extracellular cAMP, like intracellular cAMP, could up-regulate PGHS-2 expression. Surprisingly, cAMP added to extracellular medium induced a down-regulation of PGHS-2 expression in HPMECs at both mRNA and protein levels. Accordingly, the decrease by extracellular cAMP of PMA-induced PGHS-2 expression was abolished by PKI, a PKA-specific inhibitor (29) . This result indicates that a consequent activation of an ecto-PKA is required for the molecular event leading to the decrease of PGHS-2 induction. Indeed, using intact cells, labeled ATP ([␥- 32 P]ATP), and exogenous peptide kemptide (a nonpermeant specific substrate for PKA (31)), we clearly demonstrated the presence of a PKA activity at the outer surface of HPMEC membranes. In addition, the inability of PKI to cross plasmic membrane (29) supports the outer surface location of the observed PKA. Moreover, this property precludes an intracellular effect of exogenous cAMP on PMA-induced PGHS-2 expression.
This extracellular cAMP effect on PMA-induced PGHS-2 expression observed at the mRNA and protein levels was also noted for the enzymatic activity. Thus, NS-398, a selective inhibitor (30) , abolished PMA-induced PGHS-2 activity in terms of both 6-keto-PGF1␣ formation and a released inhibitory activity on platelet aggregation (data not shown). These results demonstrate that the measured PGHS activity under PMA treatment is essentially attributable to PGHS-2 isoform. Moreover, they are consistent with the recent work of Brock et al. (43) , demonstrating that PGHS-2 preferentially metabolizes arachidonic acid into PGE2 and prostacyclin, two adenylyl cyclase activators.
Furthermore, the present study reports, for the first time, opposing effects of cAMP on the PGHS-2 expression. Indeed, following its availability, cAMP exerts an up-regulation when it is increased at the intracellular level and a down-regulation when it is present in the extracellular medium. These opposing effects of cAMP suggest different cellular signaling mechanisms.
As a consequence, it is tempting to speculate that extracellular cAMP, which may be released under activation of blood platelets, for example, may reduce (through an ecto-PKA) PGHS-2 expression in HPMECs and thus attenuate an exacerbated inflammation.
Taken together, results obtained here by immunoblotting, RT-PCR, and enzyme activity are in agreement and show that extracellular cAMP decreases PGHS-2 expression in HPMECs, through an ecto-PKA signaling pathway. Besides, they outline the potential role of the inducible endothelial PGHS-2 in the limitation of platelet activation during inflammatory process. At this stage, further work will be required to establish the mechanism by which extracellular cAMP down-regulates PGHS-2 expression. In particular, it will be important to identify the ectophosphoprotein target of PKA activity at the outer surface of HPMECs and to determine the intermediate events leading to the negative regulation of PGHS-2 gene mediated by this ecto-phosphoprotein. 
